Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026, groundbreaking three-year data has confirmed the long-term efficacy of Nemluvio (nemolizumab). The long-term ARCADIA study revealed that up to 75% of adult and adolescent patients suffering from moderate-to-severe atopic dermatitis achieved a stringent EASI-90 response after 152 weeks of continuous therapy. The biological treatment acts as a highly effective IL-31RA inhibitor, showing persistent, multi-year disease control, significant reduction in severe itch, and dramatic improvements in patient sleep quality.
About the Author
